[1] |
Armstrong AW, Villanueva QDG, Echeverría CM, et al. Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab[J]. Am J Clin Dermatol, 2016,17(6):691⁃699. doi: 10.1007/s40257⁃016⁃0229⁃x.<br />
|
[2] |
Hansel K, Bianchi L, Lanza F, et al. Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance[J]. Acta Derm Venereol, 2017,97(3):346⁃350. doi: 10.2340/00015555⁃2571.<br />
|
[3] |
Asahina A, Torii H, Ohtsuki M, et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study[J]. J Dermatol, 2016,43(11):1257⁃1266. doi: 10.1111/1346⁃8138.13409.<br />
|
[4] |
Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice[J]. Arthritis Care Res (Hoboken), 2012,64(5):640⁃647. doi: 10.1002/acr.21649.<br />
|
[5] |
Armesto S, Coto⁃Segura P, Mayorga J, et al. Efficacy of adalimumab in the treatment of moderate⁃to⁃severe psoriasis: a retrospective study of 100 patients in daily practice[J]. J Dermatolog Treat, 2015,26(1):49⁃53. doi: 10.3109/09546634.2014.880775.<br />
|
[6] |
Krueger JG, Ferris LK, Menter A, et al. Anti⁃IL⁃23A mAb BI 655066 for treatment of moderate⁃to⁃severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single⁃rising⁃dose, randomized, double⁃blind, placebo⁃controlled trial[J]. J Allergy Clin Immunol, 2015,136(1):116⁃124.e7. doi: 10.1016/j.jaci.2015.01.018.<br />
|
[7] |
Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis[J]. J Am Acad Dermatol, 2010,63(3):448⁃456. doi: 10.1016/j.jaad.2009.09.040.<br />
|
[8] |
Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL[J]. J Am Acad Dermatol, 2012,66(2):241⁃251. doi: 10.1016/j.jaad.2010.12.005.<br />
|
[9] |
Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study[J]. J Eur Acad Dermatol Venereol, 2017,31(1):89⁃95. doi: 10.1111/jdv.13746.<br />
|
[10] |
Brezinski EA, Armstrong AW. An evidence⁃based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis[J]. Curr Med Chem, 2015,22(16):1930⁃1942.<br />
|
[11] |
Gilbert KE, Manalo IF, Wu JJ. Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: a systematic review[J]. J Am Acad Dermatol, 2015,73(2):329⁃331. doi: 10.1016/j.jaad.2015.04.012.<br />
|
[12] |
Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol, 2017,31(11):1853⁃1859. doi: 10.1111/jdv.14146.<br />
|